ReviewOncoTargets and therapy2019

Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date.

P D Zavras et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.